RUNX1 and heart failure: Novel therapies aimed at targeting a master-regulator transcription factor such as RUNX1 may achieve a more efficacious therapeutic response by impacting on multiple downstream signalling pathways to mitigate the adverse cardiac remodelling that initiates heart failure.